BAY 41-2272 is primarily used in research settings to study cardiovascular and pulmonary systems. It acts as a stimulator of soluble guanylate cyclase (sGC), an enzyme involved in the regulation of blood pressure and vascular tone. Researchers utilize this compound to investigate its potential therapeutic effects in conditions like hypertension, pulmonary hypertension, and heart failure. Its ability to enhance nitric oxide signaling pathways makes it a valuable tool for understanding vascular relaxation and cellular mechanisms. Additionally, BAY 41-2272 is explored for its potential anti-inflammatory and anti-fibrotic properties, which could have implications in treating chronic inflammatory diseases. Its application remains largely experimental, focusing on uncovering new insights into cardiovascular and pulmonary health.